AIM ImmunoTech Inc. Common Stock (AIM)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable advantages, and sell at a margin of safety. AIM is not that today. In fiscal 2025, the year ended 2025-12-31, revenue was only $88,000 while net loss was $14.0 million. A year earlier, fiscal 2024 revenue was $170,000 and net loss was $17.3 million, so the top line is shrinking even as the loss narrows. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $26,000 and a net loss of $3.8 million, or diluted EPS of -$0.43. That is not a business; it is a research effort funded by outside capital. Free cash flow is negative $11.7 million on a trailing basis, which, against a $5.2 million market cap at the 2026-10-13 close, gives a FairStock FCF yield of -225.5%. The company has 19 employees and no Lynch category because it has lost money in each of the last four years. There is no evidence of a moat: no scale, no pricing power, and negligible product revenue. The balance sheet shows a debt-to-equity ratio of 0.51, and FairStock’s ROE is -2,382.30% and Altman Z-score is -72.74. The P/B of 0.63 and Piotroski F-score of 5/9 suggest some asset value and accounting positives, but asset value is being consumed by losses. Valuation is speculative, tied to pipeline outcomes, not earnings. I would need much more evidence of financial staying power before calling this a value investment.

In plain English: AIM ImmunoTech is a tiny drug research company working on treatments for cancer, viral illnesses, and immune problems. It earns almost no revenue and loses millions of dollars, so the underlying business looks weak. The share price is very low, and it trades below the value of what its books say it owns, but heavy losses make it hard to call it a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer